MedTrace Logo

A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration

NCT07798375 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2026-09-01

No results posted yet for this study

Summary

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD)

Conditions

  • Neovascular Age Related Macular Degeneration(nAMD)

Interventions

BIOLOGICAL

VIS-101 6.0mg High concentration

VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

BIOLOGICAL

VIS-101 6.0mg High concentration

VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

BIOLOGICAL

VIS-101 9.0mg High concentration

VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

BIOLOGICAL

Aflibercept (Eylea)

Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

Sponsors & Collaborators

  • Visara, Inc.

    collaborator INDUSTRY

  • Everest Medicines (China) Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-05-31
Completion
2028-10-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07798375 on ClinicalTrials.gov